@article{Wang2025, 
author = {Qi Wang and Yong-yan Wang and Wei Xiao and Jin-zhou Tian and Shi-lin Chen and Li-guo Zhu and Guang-rong Sun and Da-ning Zhang and Dai-han Zhou and Guo-qiang Mei and Bao-fan Shen and Qing-guo Wang and Xi-xing Wang and Zheng Nan and Ming-xiang Han and Yue Gao and Xiao-he Xiao and Xiao-bo Sun and Kai-wen Hu and Li-qun Jia and Li Feng and Cheng-yu Wu and Xia Ding},
title = {Expert consensus on the positioning of the “Three-in-One” Registration and Evaluation Evidence System and the value of orientation of the “personal experience”},
year = {2025},
journal = {Evidence-Based Chinese Medicine and Technology Assessment},
volume = {1},
number = {1},
pages = {9570006},
keywords = {“Three-in-One”, personal experience, clinical trials, expert consensus},
url = {https://www.sciopen.com/article/10.26599/eCMTA.2025.9570006},
doi = {10.26599/eCMTA.2025.9570006},
abstract = {Traditional Chinese Medicine (TCM), as a treasure of the Chinese nation, plays a significant role in maintaining public health. In 2019, the Central Committee of the Communist Party of China and the State Council proposed for the first time the establishment of a TCM registration and evaluation evidence system that integrates TCM theory, personal experience and clinical trials (referred to as the “Three-in-One” System) to promote the inheritance and innovation of TCM. Subsequently, the National Medical Products Administration issued several guiding principles to advance the improvement and implementation of this system. Owing to the complexity of its implementation, there are still differing understandings within the TCM industry regarding the positioning of the “Three-in-One” Registration and Evaluation Evidence System, as well as the connotation and value orientation of the “personal experience.” To address this, Academician Qi Wang, President of the TCM Association, China International Exchange and Promotion Association for Medical and Healthcare and TCM master, led a group of academicians, TCM masters, TCM pharmacology experts and clinical TCM experts to convene a “Seminar on Promoting the Implementation of the ‘Three-in-One’ Registration and Evaluation Evidence System for Chinese Medicinals.” Through extensive discussions, an expert consensus was formed, clarifying the different roles of the TCM theory, “personal experience” and clinical trials within the system. It was further emphasized that the “personal experience” is the core of this system, and its data should be derived from clinical practice scenarios. In the future, the improvement of this system will require collaborative efforts across multiple fields to promote the high-quality development of the Chinese medicinal industry.}
}